Labcorp Clarifies Kratom and 7-OH Laboratory Testing Guidelines for Clinicians

Why it matters

As clinicians encounter more patients with kratom and 7-OH product use, many are uncertain whether standard drug screening catches these substances—especially new high-potency 7-OH products. Labcorp's guidance clarifies what current tests can and cannot detect, helping providers make accurate treatment decisions.

The big picture

Kratom and its synthetic derivative 7-hydroxymitragynine (7-OH) do not appear on standard opioid toxicology panels, creating a clinical blind spot in emergency, addiction, and primary care settings. Standard kratom immunoassay tests target mitragynine, the primary natural alkaloid, raising questions about whether newer 7-OH-only products might evade detection. This has created significant uncertainty for providers managing patients who may be using these substances without disclosure.

Key findings

• Current kratom immunoassay screening targets mitragynine, the primary compound in natural kratom—not 7-OH directly
• Labcorp's internal evaluation found that commercially available "7-OH" products commonly contain mitragynine as well, meaning most will still trigger a positive screen
• 7-OH isolated positivity (without mitragynine) is not commonly observed in current clinical testing data
• Definitive mass spectrometry confirmation is available and recommended when immunoassay false positives are suspected
• Clinicians are increasingly encountering patients with kratom use disorder as these products become more widely available

What they say

According to Labcorp's clinical guidance: "Although the immunoassay is not designed to detect 7-hydroxymitragynine (7-OH) directly, our internal evaluation of commercially available 7-OH products and published reports show that these products commonly contain mitragynine. As a result, the presence of mitragynine is typically sufficient to produce a positive screen in most cases."

Bottom line

Standard kratom urine screens still catch most 7-OH product users because those products typically contain mitragynine, but providers should order mass spectrometry confirmation when clinical suspicion is high and initial screens are negative.